LataMed AI Corp. (OTC: LMEDD) announced today that its 5-for-1 forward stock split has become effective, marking a significant corporate milestone as the company advances its digital health and artificial intelligence initiatives. The split, which took effect at the opening of trading following the FINRA Daily List dated July 14, 2026, is accompanied by a temporary trading symbol change to LMEDD, expected to revert to LMED after approximately twenty business days.
The forward stock split is part of a broader mandatory share exchange and the adoption of a new CUSIP number, 21116R404, replacing the previous CUSIP 21116R305. This corporate action is designed to streamline the company's capital structure and support its long-term strategy. Dr. Kevin Rodan Levy, Chief Executive Officer of LataMed AI Corp., stated: "Today's implementation of our forward stock split represents an important corporate milestone for LataMed AI. We appreciate the continued support of our shareholders and look forward to continuing the execution of our long-term strategy as we focus on expanding our telemedicine platform and pursuing commercialization opportunities for our CardioAI, PulmoAI, and NeuroAI artificial intelligence platforms."
Shareholders holding shares through brokerage accounts or in electronic book-entry form are not required to take any action, as brokerage firms and custodians are expected to process the corporate action automatically. Those holding physical stock certificates are advised that when certificates are presented to the company's transfer agent for transfer, sale, or exchange, they will be processed in accordance with the mandatory exchange procedures and exchanged for the appropriate number of post-split shares under the new CUSIP.
The forward stock split is a strategic move for LataMed AI, which is a development-stage digital health and artificial intelligence technology company focused on building telehealth infrastructure and AI-enabled healthcare solutions for emerging markets. The company's platforms, including CardioAI, PulmoAI, and NeuroAI, aim to support healthcare access, patient engagement, and provider coordination, with an initial regional focus on Latin America. The effectiveness of the split underscores the company's commitment to executing its business plan and pursuing commercialization opportunities.
For additional information, the company directs shareholders to visit https://latamed.ai or review its filings with the U.S. Securities and Exchange Commission at www.sec.gov. Shareholders with questions regarding the exchange process are encouraged to contact their brokerage firm or the company's transfer agent.
